Unit
Clinical Trials Unit
CTU · Management
Improving Patient Education Materials: A Practical Algorithm from Development to Validation
Betschart P, Staubli S, Zumstein V, Babst C, Sauter R, Schmid H, Abt D. Improving Patient Education Materials: A Practical Algorithm from Development to Validation. Curr Urol 2019; 13:64-69.
Oct 1, 2019Improving Patient Education Materials: A Practical Algorithm from Development to Validation
Oct 1, 2019Curr Urol 2019; 13:64-69
Betschart Patrick, Staubli Sergej E, Zumstein Valentin, Babst Christa, Sauter Rafael, Schmid Hans-Peter, Abt Dominik
36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry
Scheidegger O, Leupold D, Sauter R, Findling O, Rösler K, Hundsberger T. 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry. J Neurol 2018
Sep 19, 201836-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry
Sep 19, 2018J Neurol 2018
Scheidegger Olivier, Leupold Daniela, Sauter Rafael, Findling Oliver, Rösler Kai Michael, Hundsberger Thomas
Preservation of kidney function in kidney transplant recipients by alkali therapy (Preserve-Transplant Study): rationale and study protocol.
Wiegand A, Ritter A, Graf N, Arampatzis S, Sidler D, Hadaya K, Müller T, Wagner C, Wüthrich R, Mohebbi N. Preservation of kidney function in kidney transplant recipients by alkali therapy (Preserve-Transplant Study): rationale and study protocol. BMC Nephrol 2018; 19:177.
Jul 13, 2018Preservation of kidney function in kidney transplant recipients by alkali therapy (Preserve-Transplant Study): rationale and study protocol.
Jul 13, 2018BMC Nephrol 2018; 19:177
Wiegand Anna, Ritter Alexander, Graf Nicole, Arampatzis Spyridon, Sidler Daniel, Hadaya Karine, Müller Thomas F, Wagner Carsten A, Wüthrich Rudolf P, Mohebbi Nilufar
Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort
Heinimann K, von Kempis J, Sauter R, Schiff M, Sokka-Isler T, Schulze-Koops H, Müller R. Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort. J Clin Med 2018; 7
Mar 13, 2018Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort
Mar 13, 2018J Clin Med 2018; 7
Heinimann Katja, von Kempis Johannes, Sauter Rafael, Schiff Michael, Sokka-Isler Tuulikki, Schulze-Koops Hendrik, Müller Rüdiger
Heart rate variability decreases after 3 months of sustained treatment with fingolimod
Vehoff J, Haegele-Link S, Humm A, Mueller S, Sauter R, Tettenborn B, Hundsberger T. Heart rate variability decreases after 3 months of sustained treatment with fingolimod. J Neurol 2017; 264:2313-2317.
Oct 9, 2017Heart rate variability decreases after 3 months of sustained treatment with fingolimod
Oct 9, 2017J Neurol 2017; 264:2313-2317
Vehoff Jochen, Haegele-Link Stefan, Humm Andrea, Mueller Stefanie Karin, Sauter Rafael, Tettenborn Barbara, Hundsberger Thomas
Impact of human papillomavirus on outcome in patients with oropharyngeal cancer treated with primary surgery
Broglie Däppen M, Müller M, Spreitzer S, Lang F, Lutchmaya M, Stauffer E, Espeli V, Martucci F, Bongiovanni M, Foerbs D, Arnoux A, Dettmer M, Arnold A, Stöckli S, Sauter R, Pasche P, Reinhard A, de Leval L, Huber G, Pezier T, Soltermann A, Giger R, Jochum W. Impact of human papillomavirus on outcome in patients with oropharyngeal cancer treated with primary surgery. Head & neck 2017; 39:2004-2015.
Jul 10, 2017Impact of human papillomavirus on outcome in patients with oropharyngeal cancer treated with primary surgery
Jul 10, 2017Head & neck 2017; 39:2004-2015
Broglie Däppen Martina, Müller Martin, Spreitzer Stefan, Lang Florian, Lutchmaya Mathieu, Stauffer Edouard, Espeli Vittoria, Martucci Francesco, Bongiovanni Massimo, Foerbs Diana, Arnoux Andre, Dettmer Matthias, Arnold Andreas, Stöckli Sandro, Sauter Rafael, Pasche Philippe, Reinhard Antoine, de Leval Laurence, Huber Gerhard F, Pezier Thomas F, Soltermann Alex, Giger Roland, Jochum Wolfram
Heart rate variability decreases after 3 months of sustained treatment with fingolimod in patients with multiple sclerosis: a prospective clinical trial
Vehoff J, Hägele-Link S, Humm A, Müller S, Sauter R, Tettenborn B, Hundsberger T (2017). Heart rate variability decreases after 3 months of sustained treatment with fingolimod in patients with multiple sclerosis: a prospective clinical trial.
Jun 25, 2017Heart rate variability decreases after 3 months of sustained treatment with fingolimod in patients with multiple sclerosis: a prospective clinical trial
Jun 25, 20173rd EAN Congress
Vehoff Jochen, Hägele-Link Stefan, Humm Andrea, Müller Stefanie, Sauter Rafael, Tettenborn Barbara, Hundsberger Thomas
Comparative Analysis of Tumor Cell Dissemination to the Sentinel Lymph Nodes and to the Bone Marrow in Patients With Nonmetastasized Colon Cancer: A Prospective Multicenter Study
Weixler B, Viehl C, Warschkow R, Gueller U, Ramser M, Sauter R, Zuber M. Comparative Analysis of Tumor Cell Dissemination to the Sentinel Lymph Nodes and to the Bone Marrow in Patients With Nonmetastasized Colon Cancer: A Prospective Multicenter Study. JAMA Surg 2017
Jun 7, 2017Comparative Analysis of Tumor Cell Dissemination to the Sentinel Lymph Nodes and to the Bone Marrow in Patients With Nonmetastasized Colon Cancer: A Prospective Multicenter Study
Jun 7, 2017JAMA Surg 2017
Weixler Benjamin, Viehl Carsten T, Warschkow Rene, Gueller Ulrich, Ramser Michaela, Sauter Rafael, Zuber Markus
Endophenotyping in idiopathic adult onset cervical dystonia
Kägi G, Ruge D, Brugger F, Katschnig P, Sauter R, Fiorio M, Tinazzi M, Rothwell J, Bhatia K. Endophenotyping in idiopathic adult onset cervical dystonia. Clin Neurophysiol 2017; 128:1142-1147.
Apr 23, 2017Endophenotyping in idiopathic adult onset cervical dystonia
Apr 23, 2017Clin Neurophysiol 2017; 128:1142-1147
Kägi Georg, Ruge Diane, Brugger Florian, Katschnig Petra, Sauter Rafael, Fiorio Mirta, Tinazzi Michele, Rothwell John, Bhatia Kailash P
Absorption of Irrigation Fluid During Thulium Laser Vaporization of the Prostate
Muellhaupt G, Abt D, Mordasini L, Koehle O, Engeler D, Lüthi A, Sauter R, Schmid H, Schwab C. Absorption of Irrigation Fluid During Thulium Laser Vaporization of the Prostate. J Endourol 2017; 31:380-383.
Mar 1, 2017Absorption of Irrigation Fluid During Thulium Laser Vaporization of the Prostate
Mar 1, 2017J Endourol 2017; 31:380-383
Muellhaupt Gautier, Abt Dominik, Mordasini Livio, Koehle Olivia, Engeler Daniel, Lüthi Andreas, Sauter Rafael, Schmid Hans-Peter, Schwab Christoph
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial
Mey U, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Fischer N, Doerfel S, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna C, Schmid M, Schmidt-Hieber M, Driessen C. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial. Br J Haematol 2016
Dec 16, 2016Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial
Dec 16, 2016Br J Haematol 2016
Mey Ulrich J M, Ruefer Axel, Ziske Carsten, Knauf Wolfgang, Cathomas Richard, von Moos Roger, Hitz Felicitas, Sauter Rafael, Hiendlmeyer Elke, Cantoni Nathan, Bargetzi Mario, Fischer Natalie, Doerfel Steffen, Brugger Wolfram, Schwarb Heike, Pederiva Stefanie, Schwarzer Andreas, Dechow Tobias, Jehner Paul, Rauh Jacqueline, Taverna Christian J, Schmid Mathias, Schmidt-Hieber Martin, Driessen Christoph
CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART
Sauter R, Held L, Günthard H, Rougemont M, Hoffmann M, Furrer H, Cavassini M, Bernasconi E, Battegay M, Ledergerber B, Huang R. CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. Medicine (Baltimore) 2016; 95:e5094.
Oct 28, 2016CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART
Oct 28, 2016Medicine (Baltimore) 2016; 95:e5094
Sauter Rafael, Held Leonhard, Günthard Huldrych F, Rougemont Mathieu, Hoffmann Matthias, Furrer Hansjakob, Cavassini Matthias, Bernasconi Enos, Battegay Manuel, Ledergerber Bruno, Huang Ruizhu
Adaptive prior weighting in generalized regression
Held L, Sauter R. Adaptive prior weighting in generalized regression. Biometrics 2016
May 18, 2016Adaptive prior weighting in generalized regression
May 18, 2016Biometrics 2016
Held Leonhard, Sauter Rafael
Economic Aspects of Morbidity Caused by Ureteral Stents
Staubli S, Mordasini L, Engeler D, Sauter R, Schmid H, Abt D. Economic Aspects of Morbidity Caused by Ureteral Stents. Urol Int 2016; 97:91-7.
Jan 22, 2016Economic Aspects of Morbidity Caused by Ureteral Stents
Jan 22, 2016Urol Int 2016; 97:91-7
Staubli Sergej, Mordasini Livio, Engeler Daniel, Sauter Rafael, Schmid Hans-Peter, Abt Dominik
Quasi-complete separation in random effects of binary response mixed models
Sauter R, Held L. Quasi-complete separation in random effects of binary response mixed models. Journal of Statistical Computation and Simulation 2016; 86:2781-2796.
Jan 5, 2016Quasi-complete separation in random effects of binary response mixed models
Jan 5, 2016Journal of Statistical Computation and Simulation 2016; 86:2781-2796
Sauter Rafael, Held Leonhard
Economic aspects of morbidity caused by ureteral stents
Abt D, Staubli S, Mordasini L, Engeler D, Sauter R, Schmid H. Economic aspects of morbidity caused by ureteral stents. Eur Urol Suppl 2016; 15 (3):e1041.
Jan 1, 2016Economic aspects of morbidity caused by ureteral stents
Jan 1, 2016Eur Urol Suppl 2016; 15 (3):e1041
Abt Dominik, Staubli Sergej, Mordasini L, Engeler Daniel, Sauter Rafael, Schmid Hans-Peter
Oekonomische Aspekte der durch Harnleiterschienen verursachten Morbidität
Abt D, Staubli S, Engeler D, Sauter R, Schmid H. Oekonomische Aspekte der durch Harnleiterschienen verursachten Morbidität. Urologe 2016; 55 (suppl 1):100.
Jan 1, 2016Oekonomische Aspekte der durch Harnleiterschienen verursachten Morbidität
Jan 1, 2016Urologe 2016; 55 (suppl 1):100
Abt Dominik, Staubli Sergej, Engeler Daniel, Sauter Rafael, Schmid Hans-Peter
Late treatment failures in cerebrospinal fluid in patients on long-term maintenance ART with ritonavir-boosted protease PI monotherapy
Kahlert C, Bregenzer A, Gutmann C, Otterbech S, Hoffmann M, Schmid P, Vernazza P. Late treatment failures in cerebrospinal fluid in patients on long-term maintenance ART with ritonavir-boosted protease PI monotherapy. Infection 2015
Dec 11, 2015Late treatment failures in cerebrospinal fluid in patients on long-term maintenance ART with ritonavir-boosted protease PI monotherapy
Dec 11, 2015Infection 2015
Kahlert Christian, Bregenzer Andrea, Gutmann Christine, Otterbech Synove, Hoffmann Matthias, Schmid Patrick, Vernazza Pietro
Network meta-analysis with integrated nested Laplace approximations
Sauter R, Held L. Network meta-analysis with integrated nested Laplace approximations. Biometrical Journal 2015; 57:1038-1050.
Sep 11, 2015Network meta-analysis with integrated nested Laplace approximations
Sep 11, 2015Biometrical Journal 2015; 57:1038-1050
Sauter Rafael, Held Leonhard
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
Kraus M, Overkleeft H, Kisselev A, Li N, Appenzeller C, van Rooden E, Haile S, de Bruin G, van der Linden W, Shabaneh T, Silzle T, Mirabella A, Weyburne E, Geurink P, Bader J, Driessen C. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica 2015; 100:1350-60.
Jun 11, 2015The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
Jun 11, 2015Haematologica 2015; 100:1350-60
Kraus Marianne, Overkleeft Herman, Kisselev Alexei F, Li Nan, Appenzeller Christina, van Rooden Eva, Haile Sarah, de Bruin Gerjan, van der Linden Wouter A, Shabaneh Tamer B, Silzle Tobias, Mirabella Anne C, Weyburne Emily S, Geurink Paul P, Bader Juergen, Driessen Christoph